Tous les dossiers

ICO

impak Finance

3,000,000 €

impak Finance est une fintech qui a développé « impak » une marketplace et une application donnant accès à des produits et services ayant un impact social et environnemental positif.

Crosstalent

3,000,000 €

Crosstalent is a French editor that markets Cloud and SaaS software for HR and talent management.

IR PEA PEA-PME

DOSIsoft

DOSIsoft is a scientific software editor for radiotherapy and nuclear medicine.

Spotify

1,000,000 €

Spotify, the world leader in music streaming, took its first steps on the stock market on Tuesday, April 3rd in New York.

5 days, 7 hours

IR PEA PEA-PME

LISA Airplanes

1,400,000 €

Lisa Airplanes is a French company that creates, manufactures and sells a high-end two-seater seaplane. The AKOYA is the only seaplane in the world with an integrated sea foil technology.

BioBelt Anti-Moustiques

BioBelt Anti-Mosquitoes is an innovative solution that protects large areas against tiger mosquitoes. It consists of a network of interconnected traps that attract, capture and then asphyxiate mosquitoes.

Medsteer

Medsteer develops a device that reduces post-operative disorders by regulating real-time anesthesia during an operation. By relying on the patient's brain activity, the device avoids periods of deep sleep which cause many side effects.

IR PEA PEA-PME

NH TherAguix

1,000,000 €

NH TherAguix is a pharmaceutical company developing innovative nanomedicine that improves the benefits of radiotherapy without modifying current clinical methods. AGuIX® protected by 4 international patents, is currently in phase 1 on the treatment of brain metastases.

PEA PEA-PME IR ISF

Wimi

1,500,000 €

Wimi has the ambition to increase by 20% teamwork productivity. To do so, Wimi offers a digital solution integrating a complete range of services: documents sharing and Drive, tasks management, chat & channels, calendars, video conferences… Wimi is the only solution offering unified workspaces dedicated to teamwork.

PEA PEA-PME IR

AlzProtect

14,000,000 €

AlzProtect is developing AZP2006, a major step forward in the treatment of the Alzheimer's disease, and by extension, in the treatment of neurodegenerative diseases. The product AlzProtect, protected by four families of patents, is entering into the phase 1b.

InnaVirVAx

InnaVirVax develops a therapeutic vaccine against HIV, allowing for patients’ functional cure or remission. Phase I/IIa results have showed in 2015 a significant decrease of the “viral reserve”.